B-CELL LYMPHOMA

This study tests a new drug called BGB-16673, which breaks down a protein that helps cancer cells grow, combined with other treatments. It is for people with B-cell blood cancers (like lymphoma) that have returned or not responded to prior therapy. The study will enroll about 80 …

This study tests a new treatment for people with certain blood cancers (like leukemia, lymphoma, or multiple myeloma) that have come back or not responded to standard therapy. Participants receive chemotherapy followed by specially engineered natural killer (NK) cells from a dono…

This study tests whether combining two drugs, axicabtagene ciloleucel and glofitamab, can help control large B cell lymphoma that has returned or not responded to initial treatment. About 40 adults with a specific type of lymphoma will receive this combination as second-line ther…

This study tests an experimental oral drug called LP-168 in adults with B-cell lymphoma (a type of blood cancer) that has returned or stopped responding to standard treatments. The main goals are to find the safest dose and check for early signs that the drug can shrink tumors or…

This study tests a combination of two drugs—pembrolizumab and all-trans retinoic acid (ATRA)—in adults with relapsed or refractory Hodgkin lymphoma or B-Non-Hodgkin lymphoma. The goal is to see if the combo is safe and helps shrink tumors. About 24 participants will receive the t…

This study tests a new treatment called CTX112 for people with B-cell blood cancers (like lymphoma or leukemia) that have come back or not responded to standard therapy. CTX112 uses CRISPR gene-editing to create donor T-cells that target and kill cancer cells. The trial involves …

This early-phase study tests a new treatment called SynKIR-310 for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior therapies. The treatment uses a patient's own immune cells, modified to recognize and attack cancer cells. The main…

This study tests a combination of four drugs (mosunetuzumab, polatuzumab, tafasitamab, and lenalidomide) in people with relapsed B-cell non-Hodgkin lymphoma. The goal is to see if this mix can shrink or control the cancer. About 36 adults who have already tried other treatments w…

This study tests whether combining zanubrutinib and rituximab can control secondary hemophagocytic lymphohistiocytosis (HLH), a dangerous immune overreaction, in people with B-cell lymphoma. About 40 participants aged 14–80 will receive the drugs for 4 weeks along with other supp…

This early study tests a new gene therapy (LCAR02) that targets a protein called CD19 on cancer cells. Up to 18 adults with B-cell lymphoma that has returned or not responded to standard treatments will receive the therapy. The main goals are to check safety and see how well the …

This study tests a new treatment for children and young adults (ages 3-39) with B-cell cancers like leukemia or lymphoma that have come back after standard therapy. The treatment uses a patient's own immune cells, which are modified in a lab to target two cancer proteins (CD19 an…

This study is for people with certain types of B-cell or Hodgkin lymphoma. Participants first get a stem cell transplant using their own cells, then receive a targeted drug called polatuzumab vedotin every 3 weeks for up to 8 doses. The goal is to see if this approach is safe and…

This study tests a two-drug combination (mosunetuzumab and lenalidomide) as the first treatment for adults with follicular or marginal zone lymphoma. Participants start with mosunetuzumab alone, then add lenalidomide if the cancer only partially responds. The goal is to see how m…

This early-stage trial tests a new treatment called U01 (ssCART-19) for people with B-cell lymphoma that has come back or not responded to standard therapy. The study will enroll 30 participants to check safety and how well the therapy shrinks tumors. The treatment uses a patient…

This early-phase trial tests a new treatment called CLIC-2201 for people with certain blood cancers (like lymphoma or leukemia) that have not responded to standard therapy or have returned. The treatment uses a patient's own immune cells, which are modified in a lab to better rec…

This early-stage trial tests a new drug called IKS03 in people with advanced B-cell non-Hodgkin lymphoma that has not responded to other treatments. IKS03 is an antibody-drug conjugate designed to deliver a toxic payload directly to cancer cells. The study aims to find the safest…

This study is testing whether a combination of two drugs, rituximab and zanubrutinib, is safe and works well for people with untreated follicular lymphoma or marginal zone lymphoma. About 43 adults will take both drugs and be monitored for response and side effects. The goal is t…

This early-stage study tests a new type of immune cell therapy (BAFF-R CAR-T) in 30 adults with a specific form of B-cell lymphoma that has not responded to other treatments or has come back. The main goal is to check if the treatment is safe and tolerable. Researchers will also …

This study tests whether adding sonrotoclax to the standard drug zanubrutinib helps adults with mantle cell lymphoma that has returned or stopped responding to prior treatments. About 300 participants will receive either the combination or a placebo plus zanubrutinib. The main go…

This study looks at whether adding early palliative care to usual treatment helps people with multiple myeloma or aggressive B-cell lymphoma feel better. About 144 patients and their caregivers will either get early palliative care plus standard care or standard care alone. Resea…

This study looks at how the body processes venetoclax when the tablets are crushed and mixed into a liquid for children and young adults with blood cancers like leukemia or lymphoma. About 30 participants who already take venetoclax this way will have their blood levels measured.…